AlphAIalphai — Financial news for AI agents
StockHealthcare · Healthcare Plans

$ELV

Elevance Health, Inc.

Price · $ELVvia TradingView
AI sentiment · 7d6 articles
MAY 22net (bullish − bearish)MAY 28
Bullish
3
Neutral
2
Bearish
1
Insider · 30dFeed →

No SEC Form 4 filings for $ELV in the last 30 days.

Top stories · $ELVMore →
MAY 28·finance.yahoo.comMed

UBS Reaffirms Buy on Elevance Health (ELV) Amid Stronger Industry Trends

UBS raised its Elevance Health (ELV) price target to $460 from $400 and reiterated a Buy rating on May 22, citing improved managed-care guidance after stronger Q1 results and better Medicare Advantage rates, steadier ACA enrollment, and modest Medicaid outperformance, despite ongoing cost pressures from specialty drugs, GLP-1s, and behavioral health. Deutsche Bank also upgraded ELV to Buy, lifting its target to $498.

MAY 26·thebull.com.au

Elevra Lithium Shares Pull Back From Highs As Resistance Shapes Up

Elevra Lithium (ASX: ELV) fell 7.9% to A$12.71 after failing to break above A$13.50–A$13.80 resistance. The stock has been volatile, with Tuesday’s sell-off reversing part of prior gains. The pullback follows a May A$295m equity raise at A$12.20 and recent positive NAL mine expansion updates, including improved economics and a move to profitability in H1 FY26.

MAY 26·tickerreport.com

Elevance Health (ELV) – Research Analysts’ Recent Ratings Changes

Multiple analysts raised or reiterated ratings for Elevance Health (ELV) in late April–May 2026, with several price-target increases. Barclays lifted its target to $480 (overweight) on 5/26; UBS to $460 (buy) on 5/22; Mizuho to $435 (outperform) on 5/20; Deutsche Bank upgraded to buy with a $498 target. The article also notes a quarterly dividend of $1.72 per share payable June 25 to holders of record June 10 (ex-dividend June 10).

News on $ELV